|
|
|
A hallmark of EAU bladder cancer programming, the Rapid Fire Debates bring together leading experts to address some of the most pressing controversies in bladder cancer, with Ashish Kamat, MD, MBBS, moderating discussions across key clinical scenarios.
|
|
|
|
|
|
EAU 2026 IBCG Rapid Fire Debates
|
|
|
|
|
|
|
Cystoscopy vs Urinary Markers: A Debate on Bladder Cancer Surveillance Strategies
|
Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), and Laura S. Mertens, MD, PhD
Ashish Kamat moderates a debate between Jeremy Teoh and Laura Mertens on cystoscopy versus urinary markers for NMIBC surveillance.
|
|
|
|
|
|
|
|
|
|
|
|
Bladder Preservation After Neoadjuvant EV+Pembrolizumab
|
Bogdana Schmidt, MD, MPH, and Fernando Cotait Maluf, MD, PhD
Ashish Kamat moderates a debate between Bogdana Schmidt and Fernando Maluf on bladder preservation after clinical complete response to neoadjuvant therapy in MIBC.
|
|
|
|
|
|
|
|
|
|
|
|
Managing Radiation Toxicity After Trimodal Therapy for Bladder Cancer
|
Antoine Van Der Heijden, MD, PhD, and Neha Vapiwala, MD, FACR, FASTRO, FASCO
Ashish Kamat moderates a debate between Antoine van der Heijden and Neha Vapiwala on managing radiation toxicity in bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Perioperative Immunotherapy Versus Risk-Adapted Adjuvant Therapy in MIBC
|
Thomas Powles, MBBS, MRCP, MD, and Patrizia Giannatempo, MD
Ashish Kamat moderates a debate between Thomas Powles and Patrizia Giannatempo on perioperative immunotherapy in muscle-invasive bladder cancer.
|
|
|
|
|
|
|
|
|
|
|
| High-Risk BCG-Naïve NMIBC: BCG + IO – Bold New Standard or Overreach?
|
| Neal D. Shore, MD, FACS, and Ekaterina Laukhtina, MD
|
| This debate centered on whether adding checkpoint inhibition to BCG should become a new standard for BCG-naïve high-risk NMIBC. Proponents pointed to phase III evidence showing improved recurrence-related outcomes in selected high-risk patients, while opponents argued that the benefit is modest, toxicity is higher, care is more complex, and routine use may be overtreatment.
|
|
|
|
|
|
|
|
|
|
|
